Neuren Pharmaceuticals: From New Zealand roots to ASX stardom

Neuren Pharmaceuticals: From New Zealand roots to ASX stardom
Neuren's Melbourne-based CEO Jon Pilcher credits the pharmaceutical firm's breakthrough medications to NZ research. (Image: Neuren Pharmaceuticals)
Rebecca Stevenson
It was the best-performing stock on the ASX in 2023, has a market cap of about $2.2 billion, doesn’t have an office, and was founded in New Zealand. Neuren Pharmaceutical’s medication trofinetide became the first US Food and Drug Administration (FDA) approved treatment for the disabling neurological disorder Rett syndrome in March 2023. Rett syndrome is rare, “profoundly debilitating”, and mostly affects female children. It leads to developmental delays and sometimes regressions as the child ages. Neuren s...

More Markets

NZX 50 putters out; Infratil, F&P Healthcare drive weekly gain
Markets Market close

NZX 50 putters out; Infratil, F&P Healthcare drive weekly gain

The S&P/NZX 50 Index declined 63.16 points, or 0.5%, to 12,651.51.

Paul McBeth 06 Sep 2024
ASX firm snaps up NZ loyalty business
Markets

ASX firm snaps up NZ loyalty business

Gratifii will buy Rapport Group for $500,000.

John Anthony 06 Sep 2024
Jarden analysts lower Air NZ target price by 5%
Markets

Jarden analysts lower Air NZ target price by 5%

Their 12-month target price is now $0.57 versus $0.60.

Rebecca Howard 06 Sep 2024
Penno's Synlait complaint knocked back
Primary Sector

Penno's Synlait complaint knocked back

Company's founder won't be taking any further action against capital raise.

Riley Kennedy 06 Sep 2024